Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SHRH1
The experimentally established mechanism targets of Cinnarizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinnarizine SCHEMBL16225873 | 1.00 | LMNA (1.00) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL1815115 | 1.00 | LMNA (1.00) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL44957 | 1.00 | LMNA (1.00) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL3731525 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL3731524 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL10936874 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL10936878 | 0.98 | LMNA (0.97) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL11734590 | 0.93 | LMNA (0.86) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Clocinizine SCHEMBL30363 | 0.92 | LMNA (0.84) | LMNAHIF1ACYP2D6CYP3A4OPRM1 | |
| Cinnarizine SCHEMBL453260 | 0.92 | LMNA (0.84) | LMNAHIF1ACYP2D6CYP3A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12282 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4658240-A2 | PHARMACEUTICAL COMPOSITIONS FOR NASAL DELIVERY | Therakind Limited (GB) | 2025-12-10 | — | — | EP | claimed |
| US-20250360081-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | TRIASTEK INC (CN) | 2025-11-27 | — | — | US | claimed |
| EP-4604932-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2025-08-27 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| EP-4565222-A1 | MODIFIED-RELEASE ALGINATE-BASED COMPOSITION | Nutrition & Biosciences USA 1, LLC (US) | 2025-06-11 | — | — | EP | claimed |
| US-4618598-A | Method of regulating hormone function or release | DUKE UNIVERSITY (US) | 1986-10-21 | — | — | US | claimed |
| US-4612194-A | VITAMIN E, VASODILATORS | ROSHDY ISMAIL | 1986-09-16 | — | — | US | claimed |
| EP-0187639-A1 | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | KANEBO, LTD. (JP) | 1986-07-16 | — | — | EP | claimed |
| CN-85102263-A | Synthetic technique for \" new cinnarizine \ | — | 1986-05-10 | — | — | CN | claimed |
| US-4555398-A | THERMOSETTING OR THERMOPLASTIC RESIN MOLD | CHISSO CORPORATION (JP) | 1985-11-26 | — | — | US | claimed |
| US-4505914-A | BARBITURATES PLUS CINNARIZINE OR FLUNARIZINE | MERCKLE GMBH (DE) | 1985-03-19 | — | — | US | claimed |
| US-4383997-A | N-CINNAMYL-N'-BENZHYDRYLPIPERAZINE | RHEOTECH LABS, INC. | 1983-05-17 | — | — | US | claimed |
| US-4156003-A | Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine | LUDWIG MERCKLE K.G., CHEM. PHARM. FABRIK (DE) | 1979-05-22 | — | — | US | claimed |
| US-4008324-A | Phenoxyalkylcarboxylic acid salt of 1-cinnamyl-4-diphenylmethyl piperazine, method of preparation and antihypercholesteremic | LUDWIG MERCKLE KG (DT) | 1977-02-15 | — | — | US | claimed |
| US-3940485-A | Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds | LEVINSON HAROLD N | 1976-02-24 | — | — | US | claimed |